The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- Bank stocks lift Nigerian market by N609bn
- FAAN, aviation ministry meet on sector reforms
- Otti signs Abia rehabilitation centre bill into law
- Misinformation, hate speech threaten governance, democratic stability — CDD
- Innovative Biotech CEO calls for reforms to boost Nigeria’s pharmaceutical sector
- ECOWAS pushes integrated, data-driven strategy to eliminate malaria in West Africa
- Air pollution raises cancer risk by 11%, global report warns
- CBN, NCC sign pact to boost consumer protection, tackle fraud
